Q-omics provides the consensus-scored MRPL17 profile across patient tissues and cancer cell-line models. MRPL17 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MRPL17 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, MRPL17 protein abundance shows 21,036 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where MRPL17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL17 survival associations across molecular data types. MRPL17 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL17 RNA expression–survival associations across cancer types. High MRPL17 expression shows unfavorable associations in KICH, ACC, UVM, LIHC, KIRC and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MRPL17 RNA expression.
This table summarizes MRPL17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL17 shows higher tumor expression in KIRC, HNSC, COAD, BLCA, KIRP and STAD. The KIRC box plot shows higher MRPL17 RNA expression in tumor versus normal tissue (log2 FC = +1.041, t-test p < 0.001).
This table shows molecular features associated with MRPL17 in patient tissues and cancer cell lines. In patient samples, MRPL17 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
